Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Interstitial Lung Disease

Interstitial Lung Disease

Subtypes of Interstitial Lung Disease

Granulomatosis with polyangiitis 4 Langerhans cell histiocytosis 3 Pneumoconiosis 3 Silicosis 3 Radiation pneumonitis 2

36 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Interstitial Lung Disease

17 trials tracked for Interstitial Lung Disease: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 642 citations.

17Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 6 Other / NA 9
  1. Phase 3 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Completed · 642 cited
  2. Phase 4 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 Completed · 1 cited
  3. Phase 2 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Completed
  4. Phase 2 A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension Completed
  5. Phase 2 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Completed
  6. Phase 2 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease Completed
Show 11 more trials
  1. Phase 2 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Completed
  2. Phase 2 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed
  3. N/A The Natural History of Small Airways Physiology in Diseased and Healthy States Completed
  4. N/A An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease Completed
  5. N/A Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease. Completed
  6. N/A Autologous Stem Cell Treatment for Chronic Lung Disease Study Completed
  7. N/A Families-At-risk for Interstitial Lung Disease Study Completed
  8. N/A Usability and Acceptability Study of the P-STEP Mobile Application Completed
  9. N/A The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease Completed
  10. N/A Assessment of Lung Movement With Computed Tomography (CT) Completed
  11. N/A A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Interstitial Lung Disease: what the trials found

Nintedanib has been shown to result in a reduction in Chest CT Visual Score (mean changes of -4.49 and -4.06) for patients with interstitial lung disease 1. Additionally, no participants in the study experienced a 10% weight loss at either 90 or 180 days 1.

Inhaled Treprostinil demonstrated significant clinical impacts; specifically, it showed a statistically significant change in Peak 6-minute Walk Distance (6MWD) from baseline to week 12 (p=0.0041) and a significant reduction in the incidence of clinical worsening (p=0.0410) 3. Treprostinil was also evaluated in other established trials [4, 8].

Cell therapy interventions were associated with reported improvements in Quality of Life (QOL) scores at both 3 months and 6 months post-treatment across various diagnoses 17. Cell therapy was also investigated in a large cohort of patients 14.

Recent results — preliminary, needs further review

  • The P-STEP Mobile Application is currently being evaluated in a new trial 2.

For the clinician treating this condition

  • Nintedanib is associated with measurable improvements in Chest CT Visual Scores 1.
  • Inhaled Treprostinil significantly improves Peak 6-minute Walk Distance and reduces the incidence of clinical worsening 3.
  • Cell therapy has been associated with improved patient Quality of Life scores post-treatment 17.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Expert consensus guidelines for N-acetylcysteine use in various respiratory conditions
Rheumatology Guideline
Expert consensus guidelines for N-acetylcysteine use in various respiratory conditions Experts share new guidance on using N-acetylcysteine for lung health
This expert consensus guideline reviews the clinical utility of N-acetylcysteine (NAC) across several respiratory diseases. The authors sugg…
Medical experts have reached a consensus on how a specific supplement might help people managing various chronic lung diseases.
Frontiers May 4, 2026
Psoriatic arthritis linked to interstitial lung disease prevalence
Dermatology Meta-analysis
Psoriatic arthritis linked to interstitial lung disease prevalence Psoriatic Arthritis Patients Face Hidden Lung Risk Doctors Often Miss
A systematic review finds 3% of psoriatic arthritis patients have interstitial lung disease, with smoking increasing risk. Imaging-based dia…
Hidden lung scarring affects about 1 in 20 psoriatic arthritis patients, and smoking triples the risk, a new analysis shows.
May 2, 2026
Nurse and social worker telecare team intervention improved quality of life in high-risk patients with COPD, heart failure, or interstitial lung disease
Palliative Care RCT
Nurse and social worker telecare team intervention improved quality of life in high-risk patients with COPD, heart failure, or interstitial lung disease Telecare Team Helps Heart And Lung Patients Feel Better For Less Cost
This randomized clinical trial evaluated a nurse and social worker telecare team intervention (ADAPT) in high-risk patients with chronic obs…
A simple phone call from a care team can significantly improve how patients feel and function while keeping costs low.
May 1, 2026
NTCP Models Underestimate Radiation Pneumonitis Risk in Lung Cancer Patients
Oncology Cohort
NTCP Models Underestimate Radiation Pneumonitis Risk in Lung Cancer Patients New tool better predicts lung damage from radiation therapy
This cohort study of 580 lung cancer patients found that QUANTEC and Appelt NTCP models systematically underestimated radiation pneumonitis …
A new risk model more accurately predicts lung injury after modern radiation therapy for lung cancer, helping doctors tailor safer treatment…
Frontiers Apr 28, 2026
LEARNS model-based health education improves Health Education Scale scores in stable pneumoconiosis patients
Primary Care & Family Medicine RCT
LEARNS model-based health education improves Health Education Scale scores in stable pneumoconiosis patients New Education Plan Helps Lung Disease Patients Take Control
This randomized controlled trial enrolled 120 patients with stable pneumoconiosis.
Imagine waking up with a cough that won't stop.
Frontiers Apr 24, 2026
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
Allergy & Immunology Sys. Review
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma Patient with anti-PL-12 syndrome and lymphoma: a rare case report
This review of a case report describes a patient with anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma.
A single patient with anti-PL-12 antisynthetase syndrome and NK/T-cell lymphoma highlights the need for caution when interpreting rare cance…
Frontiers Apr 24, 2026
Rituximab use in interstitial pneumonia with autoimmune features shows similar outcomes to control group
Drug Pipeline Cohort
Rituximab use in interstitial pneumonia with autoimmune features shows similar outcomes to control group Rituximab shows similar outcomes for IPAF patients in small study
This retrospective case-control study of 14 rituximab-treated and 19 control patients with interstitial pneumonia with autoimmune features f…
A small study found that patients with a rare lung condition had similar outcomes whether they received rituximab or not, suggesting limited…
Frontiers Apr 24, 2026
Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.81
Pediatrics Cohort
Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.81 AI Scan Helps Doctors Spot Confusing Brain Tumors
This retrospective cohort study evaluated 93 patients with sellar region tumors to discriminate between Langerhans cell histiocytosis (LCH) …
A new computer system helps doctors tell two similar brain tumors apart using MRI scans.
Frontiers Apr 24, 2026
Brief research report on toxicity-guided TMP-SMX dose reduction in disseminated nocardiosis
Drug Pipeline Guideline
Brief research report on toxicity-guided TMP-SMX dose reduction in disseminated nocardiosis Gold miner's rare infection treated with adjusted antibiotic dose
This brief research report describes a single case of disseminated nocardiosis with CNS involvement in a patient with pneumoconiosis.
A gold miner with a rare brain infection improved after doctors lowered his antibiotic dose due to severe side effects.
Frontiers Apr 24, 2026
Narrative review examines silicate pneumoconiosis mechanisms and epidemiological links to tuberculosis
Rheumatology Sys. Review
Narrative review examines silicate pneumoconiosis mechanisms and epidemiological links to tuberculosis Why Everyday Dust Might Be Harming Your Breathing
This narrative review explores silicate pneumoconiosis and silicosis, covering human and animal populations globally.
Common dust from volcanoes and soil scars lungs just like factory work, raising risks for everyone living near these areas.
Frontiers Apr 21, 2026
Retrospective review of methylprednisolone response in children with TBX4-associated pulmonary hypertension and interstitial lung disease
Pulmonology & Critical Care
Retrospective review of methylprednisolone response in children with TBX4-associated pulmonary hypertension and interstitial lung disease Pulsed steroids may help children with TBX4-linked lung disease and pulmonary hypertension
This review examines a retrospective cohort of 21 children with TBX4-associated pulmonary hypertension treated with methylprednisolone.
Pulsed steroids helped most children with TBX4-linked lung disease improve breathing and heart function without significant side effects.
medRxiv Apr 20, 2026
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Drug Pipeline Guideline
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Frontiers Apr 19, 2026

Questions about Interstitial Lung Disease

Will a nurse and social worker telecare team improve quality of life for my lung disease?

Yes, a nurse and social worker telecare team (ADAPT) improved quality of life, health status, depression, and anxiety in patients with interstitial lung disease in a randomized trial.

Full answer →
Does smoking increase the risk of developing interstitial lung disease in arthritis patients?

Yes, smoking increases the risk of interstitial lung disease in arthritis patients, especially those with psoriatic arthritis.

Full answer →